Table 3. Impact of SSD on outcomes.
| Outcomes | SSD group (n=55) | Control group (n=45) | P‡ |
|---|---|---|---|
| Primary outcome | |||
| Microaspiration, n [%] | 49 [89] | 37 [82] | 0.469 |
| Secondary outcomes | |||
| Microaspiration of gastric contents, n [%] | 23 [42] | 13 [29] | 0.185 |
| Microaspiration of oropharyngeal secretions, n [%] | 47 [85] | 36 [80] | 0.666 |
| VAP, n [%] | 16 [29] | 11 [24] | 0.656 |
| VAT, n [%] | 7 [13] | 4 [9] | 0.750 |
| Tracheobronchial colonization, n [%] | 15 [35] | 8 [18] | 0.219 |
| Other outcomes | |||
| ICU mortality, n [%] | 27 [49] | 24 [53] | 0.693 |
| ICU length of stay (days), median (IQR) | 14 (10.0–26.0) | 15 (9.0–34.0) | 0.914§ |
| MV duration (days), median (IQR) | 10 (5.0–18.0) | 11 (7.0–28.0) | 0.158§ |
| Duration of antibiotic treatment (days), median (IQR) | 12 (8.0–19.0) | 10 (7.0–22.0) | 0.617§ |
‡, P value calculated using Fisher’s exact test, unless otherwise specified; §, P value calculated using Mann-Whitney U test. No statistically significant difference was observed. SSD, subglottic secretion drainage; ICU, intensive care unit; IQR, interquartile range; MV, mechanical ventilation, GCS, Glasgow coma scale.